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Abstract
Background: Angiogenesis appears to be a first-order event in psoriatic arthritis (PsA). Among
angiogenic factors, the cytokines vascular endothelial growth factor (VEGF), epidermal growth
factor (EGF), and fibroblast growth factors 1 and 2 (FGF1 and FGF2) play a central role in the
initiation of angiogenesis. Most of these cytokines have been shown to be upregulated in or
associated with psoriasis, rheumatoid arthritis (RA) or ankylosing spondylitis (AS). As these
diseases share common susceptibility associations with PsA, investigation of these angiogenic
factors is warranted.
Methods: Two hundred and fifty-eight patients with PsA and 154 ethnically matched controls
were genotyped using a Sequenom chip-based MALDI-TOF mass spectrometry platform. Four
SNPs in the VEGF gene, three SNPs in the EGF gene and one SNP each in FGF1 and FGF2 genes were
evaluated. Statistical analysis was performed using Fisher's exact test, and the Cochrane-Armitage
trend test. Associations with haplotypes were estimated by using weighted logistic models, where
the individual haplotype estimates were obtained using Phase v2.1.
Results: We have observed an increased frequency in the T allele of VEGF +936 (rs3025039) in
control subjects when compared to our PsA patients [Fisher's exact p-value = 0.042; OR 0.653
(95% CI: 0.434, 0.982)]. Haplotyping of markers revealed no significant associations.
Conclusion: The T allele of VEGF in +936 may act as a protective allele in the development of PsA.
Further studies regarding the role of pro-angiogenic markers in PsA are warranted.
Background
Psoriatic Arthritis (PsA) is an inflammatory form of arthri-
tis usually seronegative for rheumatoid factor [1], which
may affect as many as 30% of patients with psoriasis [2,3].
Although psoriasis and psoriatic arthritis (PsA) are inter-
related disorders, PsA is a distinct entity with its own epi-
demiological clinical and genetic features. Furthermore,
PsA demonstrates much greater heritability among first
degree relatives (λ1 48) than psoriasis (λ1 5–10) [4].
Angiogenesis appears to be a first-order event in both pso-
riasis and PsA [5]. Abnormalities in the vascular morphol-
ogy of the nail-folds of psoriasis patients without nail
disease have been observed [6], as well as an increase in
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joint tissue [7]. Recently, the peroxisome proliferator acti-
vated receptor-γ (PPARγ) agonist pioglitazone, which
inhibits angiogenesis, has shown efficacy in the treatment
of PsA in a small open-label study [8]. Modest significance
between a coding SNP of PPARγ and PsA patients has been
observed [9], suggesting that angiogenesis may be an
important area of investigation in PsA.
Among angiogenic factors, the cytokines vascular
endothelial growth factor (VEGF), epidermal growth fac-
tor (EGF), and fibroblast growth factors 1 and 2 (FGF1
and FGF2) are powerful mitogens and play a central role
in the initiation of angiogenesis. VEGF is the only mitogen
that specifically acts on endothelial cells, and has been
shown to stimulate the elongation, network formation,
and branching of nonproliferating endothelial cells in cul-
ture that are deprived of oxygen and nutrients. As
endothelial cells in tumors are routinely exposed to peri-
odic or constant hypoxia, it has been proposed that VEGF
contributes to the formation of blood vessels in tumori-
genesis [10]. FGF1 has been shown to play a role in both
angiogenesis and tumorigenesis [11], while FGF2 has
been shown to play a crucial role in both skin and carti-
lage wound healing [12,13], and in combination with
another pro-angiogenic factor synergistically induces vas-
cular networks which remain stable for more than a year
even after depletion of angiogenic factors [15]. EGF like-
wise is important in wound healing and plays a role in
tumor growth and development [16].
High levels of the cytokine VEGF have been found in the
synovial joints of both early and established rheumatoid
Arthritis (RA), PsA [17], ankylosing spondylitis, [18], and
psoriasis plaques [19]. The treatment of PsA with TNF-α
inhibitors has been shown to significantly reduce levels of
circulating VEGF and FGF1 [20].
Several VEGF polymorphisms have been associated with
the development of psoriasis [21,22]. The 936 T allele
(rs3025039) of the VEGF gene, and haplotypes at posi-
tions -2578 (rs699947), -1154 (rs1570360), -634
(rs2010963) and 936 have been associated with younger
age of onset of RA in a Korean population [23]. Further-
more a haplotype of SNPs at positions -2578, -1154 and -
634 has been associated with disease severity for ankylos-
ing spondylitis in the same population [24].
Both FGF1 and FGF2 have been observed to be upregu-
lated in the synovial tissue of human subjects with RA
[25] and significantly worsened clinical symptoms in a rat
adjuvant-induced model of arthritis [26], while at least
one polymorphism of the EGF gene (rs4444903) has been
shown to significantly affect EGF production [27]. At the
current time, genetic variations in the FGF1, FGF2 or EGF
genes have not been studied in either RA or the spondy-
loarthropathies.
Given the previously reported associations of VEGF in
both RA and AS, and the role that VEGF, FGF1, FGF2 and
EGF play in angiogenesis, we examined genetic variants of
each of these genes in PsA subjects from Newfoundland.
Methods
This study was approved by the local ethics committee of
Memorial University of Newfoundland. Informed con-
sent was obtained from all patients. All PsA probands
were Caucasians from the Newfoundland population. PsA
was diagnosed as inflammatory arthritis in patients with
psoriasis, in the absence of any other etiology for inflam-
matory arthritis. Information was collected systematically
and included age at onset of psoriasis, PsA and disease
pattern. The ethnically matched, healthy control subjects
were also obtained from the Newfoundland population,
and were unrelated to the cases.
Whole blood samples were obtained from PsA probands
and control subjects. DNA was extracted using the
Promega Wizard Genomic DNA purification Kit. The
detection of SNPs was performed by the analysis of primer
extension products generated from previously amplified
genomic DNA using a Sequenom chip-based MALDI-TOF
mass spectrometry platform. In brief, PCR and extension
reactions were designed using MassARRAY design soft-
ware, and were carried out using 2.5 ng of template DNA.
Unincorporated nucleotides in the PCR product were
deactivated using shrimp alkaline phosphatase. The
amplification of the SNP site was carried out using the
MassExtend primer and involved the use of specific d/
ddNTP termination mixes which were also determined
using MassARRAY assay design software. The primer
extension products were then cleaned and spotted onto a
SpectroChip. The chips were scanned using a mass spec-
trometry workstation (Bruker) and the resulting spectra
were analyzed and genotypes were determined using the
Sequenom SpectroTYPER-RT software. We genotyped PsA
probands and control subjects for the following polymor-
phisms: in the VEGF gene rs3025039, rs699947,
rs1570360, and rs2010963; in the FGF1 gene rs34011; in
the FGF2 gene rs1048201; and in the EGF gene
rs4444903, rs11568943 and rs2237051.
For 2 × 2 contingency tables of allele frequencies, Fisher's
exact tests were conducted to calculate the exact p-values,
and odds ratios were also calculated. As supporting
exploratory analyses, genotype frequencies were also
examined: for each of the 2 × 3 contingency tables of gen-
otype frequencies, two different statistical methods that
require somewhat different modeling assumptions were
used to generate p-values: one was Fisher's exact test, andPage 2 of 7
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may have more power than Fisher's exact test if a trend
exists across genotype categories under the additive
genetic effect model.
Haplotype estimation was conducted in several stages
using two software packages (Haploview [28] and Phase
v2.1 [29,30]): Haploview was first run on the markers for
each multi-marker gene to identify the linkage disequilib-
rium structure and check to ensure that the markers were
appropriate for inclusion in the haplotype estimates.
Once the markers for which haplotypes were to be con-
structed were identified for each gene, then Haploview
was re-run to identify the likely haplotypes and determine
their relative frequencies. In order to predict the haplo-
types for each subject, the Phase software was run on the
markers used for Haploview. Haplotyping was performed
on the genes EGF and VEGF only, as there was only one
genotyped marker in each of FGF1 and FGF2. Haplotype
odds ratios for disease associations were calculated using
the mixture logistic regression method proposed by Sham
et al. (2004) [31], fitted by using WinBUGS 1.4 (Medical
Research Council Biostatistics Unit, Cambridge) [32],
which estimates Bayesian model parameters by using
Markov chain Monte Carlo methods.
Results
Two hundred and fifty-eight PsA probands and 154 ethni-
cally matched controls were studied. All subjects were
Caucasian of North European descent and considered to
be native Newfoundlanders. The mean age of PsA patients
at the time of study was 49.67 years (sd 10.95 years), and
48.5% of subjects were females. The mean age of onset of
psoriasis in our cohort was 29.27 years (sd 14.16 years).
Not all SNPs were successfully genotyped in every individ-
ual. The results of the genotyping experiments are given in
Table 1.
Chi squared (χ2) tests for departure from the Hardy-Wein-
berg equilibrium were performed on each marker by Hap-
loview The only marker that attained statistical
significance in the control sample is rs4444903 in EGF
gene (p < 0.01), and this marker was removed from fur-
ther analysis; All the other markers satisfied H-W equilib-
rium.
The marker VEGF +936 (rs3025039) yielded a statistically
significant result when Fisher's exact test was performed to
compare allele frequencies between cases and controls
(see Table 1). There was a higher proportion of T alleles
among controls than cases (cases 11.6% vs. 16.8% in con-
trols); Fisher's exact p-value = 0.042, OR for the T allele:
0.653 (95% CI: 0.434, 0.982). This finding is consistent
with those of the statistical tests on the genotype frequen-
cies (Fisher's exact test p = 0.082; Trend test p = 0.035).
The marker VEGF -634 (rs2010963) also appears to yield
a statistically significant result when Fisher's exact test was
performed on the genotype frequencies (p = 0.037). How-
ever, neither the Fisher's exact test on the allele table (p =
0.74) nor the trend test on the genotype table (p = 0.71)
was statistically significant. The remaining two SNPs in
the VEGF gene, VEGF -1154 (rs1570360) nor VEGF -2578
(rs699947) displayed no evidence of an association with
PsA. For the FGF1 and FGF2 markers (rs34011 and
rs1048201 respectively), there were no statistically signif-
icant findings in any of the tests (p > 0.5) that would sug-
gest an association with PsA. For the two EGF SNPs, there
was no evidence of association for either rs2237051 or
rs11568943 in PsA.
The VEGF marker +936 (rs3025039) is visibly physically
far from, and has low LD with, the other 3 markers in the
gene. Thus, it was decided that rs3025039 should be
excluded when estimating multi-marker haplotypes
within this gene, (this decision is consistent with the
VEGF haplotyping work of Seo et al [24]) and only
rs699947, rs1570360, and rs2010963 were considered for
haplotyping. There are 3 main haplotypes (AAG, CGC,
and CGG) at the loci rs699947, rs1570360, and
rs2010963, and haplotype frequency estimates are shown
in Table 2. Haploview performed χ2 tests comparing fre-
quencies of haplotype CGC and CGG, respectively, in
cases and controls. For CGC, the haplotype frequency was
0.325 in controls and 0.308 in cases, while the χ2 test gave
a p value of 0.612. For CGG the haplotype frequency was
0.138 in controls and 0.186 in cases, while the χ2 test gave
a p value of 0.077.
In order to calculate haplotype odds ratios (HOR), Phase
v2.1 was used to make haplotype predictions for individ-
uals. The haplotype frequencies generated by Phase and
Haploview were compared and it was determined that the
results from the two software packages were consistent
with each other. A logistic regression model was then fit-
ted to the case-control data to determine the odds ratio
associated with each haplotype. Since haplotypes for
some individuals cannot be precisely determined due to
phase ambiguities, the mixture logistic regression method
[31] was used to account for the probabilistic determina-
tion of haplotypes for individuals. This was implemented
in WinBUGS 1.4. Note that this implementation does not
yield p-values due to its Bayesian nature, but statistical sig-
nificance can still be assessed by checking whether the
95% CI of HOR spans 1.0.
The results of the HOR analysis for the EGF and VEGF
markers are given in Tables 3 and 4. Neither of the haplo-
types for either gene was found to be strongly related to
the disease status. It was decided that the marker
rs4444903 of the EGF gene should be excluded from hap-Page 3 of 7
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the control sample. Thus, only EGF markers rs11568943
and rs2237051 were considered for haplotyping. No evi-
dence of a haplotype association with PsA for EGF mark-
ers (rs11568943 and rs2237051) was observed.
Of the 258 PsA probands, 164 had polyarticular disease
(63.6%); 79 had oligoarticular disease (30.6%); 5 patients
had isolated DIP variant (1.9%), 5 had isolated spondy-
loarthropathies (1.9%) and 3 had arthritis mutilans
(1.1%).
Due to the low frequency of the isolated DIP, isolated
spondylitis, and arthritis mutilans variant, we assessed
differences in allele frequencies for our markers in
between the oligoarticular and polyarticular subtypes of
PsA, (data summarized in Table 5).
With respect to axial involvement, as noted above isolated
spondylitis was relatively rare in our cohort. Most of the
cases of spondylitis occurred in conjunction with either
oligoarthritis or polyarthritis. Thus we stratified our PsA
probands as having spondylitis or no spondylitis irrespec-
tive of peripheral involvement. We noted that 40 (15.5%)
of our patients had a concomitant spondyloarthropathy
and 201 patients (78.0%) had no axial involvement. For
the remaining 17 patients there was insufficient informa-
tion to properly assess for the presence of spondylitis
(data summarized in Table 6). As noted in tables 5 and 6,
no significant differences in minor allele frequencies were
Table 1: Genotype frequencies of SNPs in VEGF, FGF1 FGF2 and EGF in PsA patients and controls
Genotype NF PsA patients Controls
VEGF+936 CC 200/258 (77.5%) 100/146 (68.5%)
rs3025039 CT 56/258 (21.7%) 43/146 (29.5%)
TT 2/258 (0.8%) 3/146 (2.0%)
Allele Freq (T) 11.6% 16.8%
VEGF-1154 GG 69/257 (26.8%) 35/147 (23.8%)
rs1570360 GA 121/257 (47.1%) 69/147 (46.9%)
AA 67/257 (26.1%) 43/147 (29.3%)
Allele Freq (A) 49.6% 52.7%
VEGF-2578 AA 68/257 (26.5%) 45/150 (30.0%)
rs699947 AC 124/257 (48.2%) 70/150 (46.7%)
CC 65/257 (25.3%) 35/150 (23.3%)
Allele Freq (C) 49.4% 46.7%
VEGF-634 GG 118/255 (46.3%) 64/127 (50.4%)
rs2010963 GC 118/255 (46.3%) 45/127 (35.4%)
CC 19/255 (7.4%) 18/127 (14.2%)
Allele Freq (c) 30.6% 31.9%
FGF1 CC 110/242 (45.5%) 74/154 (48.0%)
rs34011 CT 108/242 (44.6%) 64/154 (41.6%)
TT 24/242 (9.9%) 16/154 (10.4%)
Allele Freq (T) 32.2% 31.2%
FGF2 CC 167/254 (65.7%) 99/154 (64.3%)
rs1048201 CT 79/254 (31.1%) 47/154 (30.5%)
TT 8/254 (3.2%) 8/154 (5.2%)
Allele Freq (T) 18.7% 20.5%
EGF AA 209/248 (84.3%) 122/153 (79.7%)
rs4444903 GA 4/248 (1.6%) 1/153 (0.7%)
GG 35/248 (14.1%) 30/153 (19.6%)
Allele Freq (G) 14.9% 19.9%
EGF GG 78/256 (30.5%) 55/154 (35.7%)
rs2237051 GA 138/256 (53.9%) 72/154 (46.8%)
AA 40/256 (15.6%) 27/154 (17.5%)
Allele Freq (A) 42.6% 40.9%
EGF GG 233/243 (95.9%) 140/149 (94.0%)
rs11568943 GA 10/243 (4.1%) 9/149 (6.0%)
AA 0 0
Allele Freq (A) 2.1% 3.0%Page 4 of 7
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ined in our study using Fisher's exact test.
Discussion
The proposed physiological role of the cytokines coded
for by the VEGF, FGF1, FGF2 and EGF genes, along with
the increased levels of these angiogenic factors in arthritic
synovium, make these worthy targets for evaluation of
genetic association study.
We have observed an increased frequency in the T allele of
VEGF +936 (rs3025039) in control subjects when com-
pared to our PsA patients [Fisher's exact p-value = 0.042;
OR 0.653 (95% CI: 0.434, 0.982)] indicating that this
SNP may play a protective role against the development of
PsA. This is in contrast to Han et al. [23] who observed an
association of the T allele with the development of RA. It
is worth noting that the pattern of increasing vascularity in
PsA synovial tissue has been shown to be markedly dis-
tinct from that observed in RA: PsA patients were shown
to have predominantly tortuous, bushy vessels while RA
patients had mainly straight, branching vessels [33]. This
potentially indicates differing mechanisms of angiogen-
esis, lending further evidence to the idea that there are
indeed different pathogenic mechanisms in RA and PsA,
which is not necessarily surprising.
Although the -1154 G→A (rs1570360) and -634 G→C
(rs2010963) VEGF variants were not associated with rheu-
matoid arthritis in white population from Spain [34],
interesting observations were found in assessing patients
with primary systemic vasculitides from North-western
Spain. With respect to this, biopsy-proven giant cell arteri-
tis (GCA) patients, who had severe ischemic complica-
tions exhibited a significantly increased frequency of
VEGF -634 G allele compared with GCA patients not
affected by ischemic complications or with healthy con-
trols. Interestingly, patients carrying the VEGF -634 C
allele, associated with high production of VEGF had sig-
nificantly reduced frequency of severe ischemic events in
the setting of this large and middle-sized blood vessel vas-
culitis. In this regard, the carriage rate of the risk allele G
showed statistically significant skewing comparing GCA
patients with severe ischemic events with the remaining
GCA patients (GG + GC compared with CC). These results
suggest a potential implication of the VEGF gene -634 G--
>C polymorphism in the development of severe ischemic
manifestations of GCA. High VEGF levels may have a
compensatory effect supporting neoangiogenesis mecha-
nisms that may protect GCA patients from the develop-
ment of severe ischemic complications such as irreversible
visual loss [35]. In contrast, in Henoch-Schonlein Purpura
(HSP), a small-sized blood vessel vasculitis involving
skin, gut and kidney, the high VEGF producing -1154 G
allele was increased in HSP patients with nephritis com-
pared with healthy controls. Similarly, the high VEGF pro-
ducing -634 C allele was also increased in patients with
nephritis compared to controls. The -1154G/-634C hap-
lotype was also associated with susceptibility to HSP
nephritis. Moreover, a protective effect against nephritis in
patients with HSP was observed for the -1154A/-634G
VEGF promoter haplotype. These results also suggest a
potential implication of the VEGF -1154 G-->A and -634
G-->C polymorphisms in the development of nephritis in
patients with HSP [36]. It is also worth noting that in sev-
eral instances the frequency of disease-associated and
other alleles have been shown to be markedly different
between Caucasian and Asian populations [35,36] includ-
ing alleles associated with RA and other auto-immune
conditions [37], therefore, our observed differences in the
allele frequency of VEGF +936 (rs3025039) from other
published reports is not surprising.
Conclusion
Thus, the first investigation of genetic variations of the
pro-angiogenic cytokines VEGF, FGF1, FGF2, and EGF in
Table 2: Haplotype frequencies for VEGF rs699947, rs1570360, and rs2010963, estimated by using PHASE version 2.1.
Haplotype Frequency in PsA cases (N = 516) No. (%) Frequency in controls (N = 300) No. (%)
CGC 159.0 (30.8%) 97.6 (32.5%)
CGG 96.0 (18.6%) 41.4 (13.8%)
AAG 256.0 (49.6%) 156.9 (52.3%)
All other haplotypes 5 (0.97%) 4.1 (1.4%)
Table 3: Haplotype Odds Ratios (HOR) for PsA associated with EGF rs11568943 and rs2237051. The baseline haplotype for reference 
is GG.
EGF haplotype HOR (95% CI)
GA 1.106 (0.824, 1.504)
AA 0.702 (0.264, 1.844)Page 5 of 7
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that the T allele of VEGF in +936 may act as a protective
allele in the development of PsA, in contrast to other
reports which have observed a higher frequency of the
allele in RA patients. The possibility does remain that an
association exists for novel SNPs in these genes which
may affect transcription levels or cause other functional
changes, or within regulatory genes for VEGF, FGF1, FGF2
and EGF. It is also quite possible that variants in genes for
other molecules which function in angiogenesis may play
a role in PsA. Further studies regarding the role of pro-ang-
iogenic markers in PsA would be beneficial to help eluci-
date pathogenic pathways in this disease.
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FGF1 (T) rs34011 0.32 0.36
FGF2 (T) rs1048201 0.21 0.21
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